Related Experiment Video
Updated: Sep 14, 2025
Software-Assisted Quantitative Measurement of Osteoarthritic Subchondral Bone Thickness
Published on: March 18, 2022
Asperosaponin VI mitigates mitochondrial dysfunction and chondrocyte apoptosis in osteoarthritis by modulating the
Jie Qiao1,2, Ruibing Feng1,2, Gongxu Yang2
1Department of Orthopedics, Ceneral Hospital of Central Theater Command, No.627 Wuluo Road, Wuchang District, Wuhan, Hubei, China.
Objective:
To investigate the therapeutic potential of Asperosaponin VI (ASA VI) from Clematis chinensis in mitigating osteoarthritis (OA) progression by modulating the AMPK-SIRT3 pathway, specifically addressing ER stress, mitochondrial dysfunction, and chondrocyte apoptosis.
Methods:
In vitro studies were conducted using tert-Butyl hydroperoxide (TBHP)-treated chondrocytes to evaluate the effects of ASA VI on apoptosis, extracellular matrix (ECM) degradation, and mitochondrial function. In vivo studies were performed using a Destabilization of the Medial Meniscus (DMM) rat model to assess cartilage protection and joint integrity. Key molecular markers of ER stress (GRP78, CHOP, ATF4) and mitochondrial biogenesis (PGC-1α, TFAM, NRF-2) were analyzed through Western blotting and PCR. Histological assessments, including Safranin O and H&E staining, were used to evaluate joint architecture and cartilage degradation, while Osteoarthritis Research Society International (OARSI) scores quantified the extent of cartilage destruction.
Results:
ASA VI treatment significantly enhanced chondrocyte viability and reduced apoptosis, as evidenced by a decrease in TUNEL-positive cells. It also preserved cartilage matrix integrity by upregulating Collagen II and Aggrecan, while reducing MMP-13 expression. Mechanistic studies revealed that ASA VI activates the AMPK-SIRT3 pathway, reducing ER stress and enhancing mitochondrial biogenesis, as indicated by increased PGC-1α, TFAM, and NRF-2 expression. Improvements in mitochondrial function were confirmed by increased ATP production and the preservation of mitochondrial membrane potential. In the DMM rat model, ASA VI treatment led to a significant reduction in cartilage degradation and OARSI scores, with histological analysis confirming improved joint architecture. Molecular analysis further validated the reduction in ER stress markers, linking these improvements to the activation of the AMPK-SIRT3 pathway.
Conclusion:
ASA VI from Clematis chinensis offers a promising therapeutic approach for OA by leveraging the AMPK-SIRT3 pathway to alleviate ER stress and mitochondrial dysfunction. This comprehensive protective mechanism contributes to reduced chondrocyte apoptosis and preserved cartilage integrity, highlighting ASA VI's potential as a novel disease-modifying agent in OA management.
Insights
Asperosaponin VI (ASA VI) from Clematis chinensis protects against osteoarthritis by activating the AMPK-SIRT3 pathway. This treatment reduces endoplasmic reticulum stress and mitochondrial dysfunction, preserving cartilage integrity and chondrocyte viability.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage degradation, chondrocyte apoptosis, endoplasmic reticulum (ER) stress, and mitochondrial dysfunction.
- Current OA treatments primarily manage symptoms, lacking disease-modifying capabilities.
- Identifying novel therapeutic agents that target underlying pathological mechanisms is crucial for effective OA management.
Purpose of the Study:
- To investigate the therapeutic potential of Asperosaponin VI (ASA VI), a compound derived from Clematis chinensis, in mitigating osteoarthritis (OA) progression.
- To elucidate the role of the AMPK-SIRT3 pathway in mediating the protective effects of ASA VI against ER stress, mitochondrial dysfunction, and chondrocyte apoptosis in OA.
- To evaluate the efficacy of ASA VI in both in vitro and in vivo models of OA.
Main Methods:
- In vitro studies utilized tert-Butyl hydroperoxide (TBHP)-treated chondrocytes to assess ASA VI's impact on apoptosis, extracellular matrix (ECM) degradation, and mitochondrial function.
- In vivo studies employed a Destabilization of the Medial Meniscus (DMM) rat model to evaluate ASA VI's cartilage-protective effects and impact on joint integrity.
- Molecular analyses included Western blotting and PCR to measure key markers of ER stress (GRP78, CHOP, ATF4) and mitochondrial biogenesis (PGC-1α, TFAM, NRF-2). Histological assessments (Safranin O, H&E staining) and Osteoarthritis Research Society International (OARSI) scores were used to quantify cartilage damage and joint architecture.
Main Results:
- ASA VI significantly enhanced chondrocyte viability and reduced apoptosis, preserving cartilage matrix integrity by upregulating Collagen II and Aggrecan while decreasing MMP-13 expression.
- Mechanistic studies demonstrated that ASA VI activates the AMPK-SIRT3 pathway, leading to reduced ER stress and enhanced mitochondrial biogenesis (increased PGC-1α, TFAM, NRF-2).
- In the DMM rat model, ASA VI treatment significantly reduced cartilage degradation and OARSI scores, with histological evidence of improved joint architecture and reduced ER stress markers.
Conclusions:
- Asperosaponin VI (ASA VI) from Clematis chinensis demonstrates significant therapeutic potential for osteoarthritis.
- ASA VI effectively alleviates ER stress and mitochondrial dysfunction by activating the AMPK-SIRT3 pathway, thereby reducing chondrocyte apoptosis and preserving cartilage integrity.
- These findings highlight ASA VI as a promising novel disease-modifying agent for osteoarthritis management.
